KALA BIO to Present at Jefferies Global Healthcare Conference
KALA BIO (NASDAQ: KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET in New York, NY. Additionally, the management team will be available for one-on-one meetings throughout the day. Interested parties can access the webcast and subsequent recording through the "Presentations" section on KALA's website at www.kalarx.com.
KALA BIO (NASDAQ: KALA), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie innovative per le malattie oculari, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il management dell'azienda terrà una presentazione il giovedì 5 giugno 2025 alle 13:25 ET a New York, NY. Inoltre, il team dirigenziale sarà disponibile per incontri individuali durante tutta la giornata. Gli interessati potranno accedere alla diretta streaming e alla registrazione successiva nella sezione "Presentazioni" del sito web di KALA all'indirizzo www.kalarx.com.
KALA BIO (NASDAQ: KALA), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar terapias innovadoras para enfermedades oculares, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. La dirección de la empresa realizará una presentación el jueves 5 de junio de 2025 a la 1:25 p.m. ET en Nueva York, NY. Además, el equipo directivo estará disponible para reuniones individuales durante todo el día. Las partes interesadas pueden acceder a la transmisión en vivo y a la grabación posterior a través de la sección "Presentaciones" en el sitio web de KALA en www.kalarx.com.
KALA BIO (NASDAQ: KALA)는 혁신적인 안과 질환 치료제를 개발하는 임상 단계의 바이오제약 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여할 것임을 발표했습니다. 회사 경영진은 2025년 6월 5일 목요일 오후 1시 25분(동부시간) 뉴욕에서 프레젠테이션을 진행할 예정입니다. 또한, 경영진은 하루 종일 1:1 미팅도 진행할 예정입니다. 관심 있는 분들은 KALA 웹사이트(www.kalarx.com)의 "Presentations" 섹션을 통해 웹캐스트와 녹화 영상을 시청할 수 있습니다.
KALA BIO (NASDAQ : KALA), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies innovantes pour les maladies oculaires, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La direction de l'entreprise présentera le jeudi 5 juin 2025 à 13h25 ET à New York, NY. De plus, l'équipe dirigeante sera disponible pour des réunions individuelles tout au long de la journée. Les personnes intéressées peuvent accéder au webdiffusion et à l'enregistrement ultérieur via la section « Présentations » sur le site web de KALA à l'adresse www.kalarx.com.
KALA BIO (NASDAQ: KALA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung innovativer Therapien für Augenerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 13:25 Uhr ET in New York, NY, eine Präsentation halten. Außerdem steht das Management-Team den ganzen Tag über für Einzelgespräche zur Verfügung. Interessierte können den Webcast und die anschließende Aufzeichnung über den Bereich "Präsentationen" auf der Website von KALA unter www.kalarx.com abrufen.
- None.
- None.
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When is KALA BIO presenting at the Jefferies Global Healthcare Conference 2025?
How can investors access KALA BIO's Jefferies conference presentation?
What is KALA BIO's main business focus?
Will KALA BIO management be available for individual meetings at the Jefferies conference?
